MITF-siRNA formulation is a safe and effective therapy for human melasma
about
Confetti-like Sparing: A Diagnostic Clinical Feature of MelasmaNucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.Progress toward in vivo use of siRNAs-IIMicroRNA-218 inhibits melanogenesis by directly suppressing microphthalmia-associated transcription factor expression.Knock-down of ABCE1 gene induces G1/S arrest in human oral cancer cells.Depleting ABCE1 expression induces apoptosis and inhibits the ability of proliferation and migration of human esophageal carcinoma cells.Topical delivery of siRNA into skin using SPACE-peptide carriers.siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Visualization of plasmid delivery to keratinocytes in mouse and human epidermis.Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation.Effect of silencing SATB1 on proliferation, invasion and apoptosis of A549 human lung adenocarcinoma cellsGenomic and functional characterizations of phosphodiesterase subtype 4D in human cancersmiRNAs in inflammatory skin diseases and their clinical implications.microRNAs in Psoriasis.Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease.Advances in the Application and Impact of MicroRNAs as Therapies for Skin DiseaseThe changes of microRNA expression profiles and tyrosinase related proteins in MITF knocked down melanocytes.
P2860
Q26752186-5A25A74C-39BE-423C-88D9-176DA7BD9CFAQ28085200-A23BBEEA-74D1-4851-AEF4-926E070F59A1Q28255877-BF4E8463-197A-4D76-9468-2AD3D8411CE4Q34143012-39943466-5DCA-40B5-A713-345CF98CFBD1Q34371150-A8295660-8946-43A1-90B2-9CB5A12A03EAQ35097836-69389F25-0B61-4E7E-A553-173EF70FA9DBQ35587915-0F7AEB8B-4156-4495-A353-786D338085F8Q35590281-31480AE5-76BF-4E51-84E2-A83A9CA638BBQ35619666-323C3733-35AC-45C4-A672-5123E1570C82Q36132897-7F5EE6E2-1930-4CA3-A7C6-AE109654A8F3Q36206228-BB805E9C-7900-46B5-A2A7-7C82BC5C3E6EQ36762760-9FEED2F2-5584-4B78-91CF-8366F1661277Q38365504-96E3D454-889A-4C83-B51F-2D693F810C28Q38708656-5C1A0741-D011-478D-8334-EDFEAC6E93B3Q39406180-33BA33E5-A911-41EE-8DCD-838345D24C8BQ42362861-60E6041E-8D71-4B3F-A9E8-84997270F444Q54296428-1C29C4FD-4095-4DE2-BEDF-63D211B26AB2
P2860
MITF-siRNA formulation is a safe and effective therapy for human melasma
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MITF-siRNA formulation is a safe and effective therapy for human melasma
@ast
MITF-siRNA formulation is a safe and effective therapy for human melasma
@en
MITF-siRNA formulation is a safe and effective therapy for human melasma
@nl
type
label
MITF-siRNA formulation is a safe and effective therapy for human melasma
@ast
MITF-siRNA formulation is a safe and effective therapy for human melasma
@en
MITF-siRNA formulation is a safe and effective therapy for human melasma
@nl
prefLabel
MITF-siRNA formulation is a safe and effective therapy for human melasma
@ast
MITF-siRNA formulation is a safe and effective therapy for human melasma
@en
MITF-siRNA formulation is a safe and effective therapy for human melasma
@nl
P2093
P2860
P356
P1433
P1476
MITF-siRNA formulation is a safe and effective therapy for human melasma
@en
P2093
Fangyuan Que
Guang Zhao
Henming Jia
Hongjie Zhang
James Q Yin
Qingqi Yang
Rusong Meng
P2860
P304
P356
10.1038/MT.2010.263
P577
2010-11-30T00:00:00Z